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as resistaTo the Editor,
We agree with Pholwat et al. [1] that fast genotypic methods
will play an increasingly prominent role in drug-susceptibility
testing (DST) for the Mycobacterium tuberculosis complex (MTBC)
[2]. They reported on the evaluation of a high-resolution melt
assay (HMR) to detect pyrazinamide (PZA) resistance, which has
the advantage of speed and simplicity. Two of 96 test isolates
were PZA susceptible but contained a synonymous pncAll major MTBC lineages [11]. Only th
es from other lineages had the tcC va
he spoligotypes for the lineage 3 iso
r Ltd. This is an open access article) tcC/tcT Ser65Ser mutation and were falsely classiﬁed
nt by HMR. The isolates in this study came almost exclu-
sively from two countries (Thailand and Tanzania), and we ques-
tioned how disseminated this mutation was in the MTBC
population at large. A literature review suggested that this silent
mutation is largely speciﬁc to the Central Asian (CAS) genotype,
although not all CAS strains harbour this polymorphism [3e10].
We also sought the mutation in a globally representative collec-
tion of MTBC genomes (n ¼ 219), which conﬁrmed these ﬁndings
(Figure 1) [11]. 83% of the isolates of the East African-Indian line-
age 3, which encompasses the CAS genotype [12], shared the mu-
tation in question, whereas the 6 most phylogenetically basal
lineage 3 isolates lacked the polymorphism. These isolates were
not easily identiﬁable using spoligotyping alone as they included
a number of Shared International Types (SITs): SIT1 (pseudo-e more phylogenetically recent lineage 3 isolates shared the pncA tcT variant at Ser65,
riant (including the lineage 4M. tuberculosis H37Rv laboratory strain that is used as the
lates can be found in Supplemental Figure 1.
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Letter to the Editor / Tuberculosis 94 (2014) 451e453452Beijing [13,14]), SIT26, SIT486 and SIT1200. In fact, SIT26, the most
frequent CAS spoligotype globally [15], was paraphyletic (i.e. it
included isolates with and without the synonymous mutation
(Supplemental Figure 1)).
The data by Pholwat et al. are in agreement with our ﬁndings as
they found this synonymous mutation in 7/15 (47%) of Tanzanian
isolates, where lineage 3 strains are known to be dominant
[12,16], and in none of the isolates from Thailand or the United
States, where lineage 3 strains are rare [12,17]. As a result, the spec-
iﬁcity of their HMR assay depends on the local MTBC population
structure (i.e. in countries in which lineage 3 isolates are wide-
spread the number of false-resistant results will likely exceed the
number of true-positives). By contrast, the Nipro Corporation
avoided this ﬂaw by including an additional probe to compensate
for the Ser65Ser polymorphism when designing their pncA line
probe assay [18,19]. This underlines that the MTBC diversity has
to be considered when designing and validating genotypic DST as-
says [19,20].
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